Sign In
Buy AMRX
$16.66
+0.550 (+3.41%)
At Close: Jun 23, 2026
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
10:17am, Thursday, 11'th Jun 2026
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally? GF Value Says Overvalued
08:17pm, Wednesday, 10'th Jun 2026
On June 10, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 4.4% today, bringing the current price to $15.32. This price is within a 52-week range that has
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
11:00am, Wednesday, 10'th Jun 2026
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR Newswire NASHVI
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
10:09am, Wednesday, 10'th Jun 2026
Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide NASHVILLE, Tenn., June 10, 2026 /PRNewswire/ -- Dispensary of Hope announce
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
03:05pm, Tuesday, 09'th Jun 2026
Amneal Pharmaceuticals NASDAQ: AMRX Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
01:32pm, Tuesday, 09'th Jun 2026
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
01:20pm, Tuesday, 09'th Jun 2026
AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.
Is Amneal a Buy Before Rytary Generic Erosion?
01:01pm, Tuesday, 09'th Jun 2026
AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.
What's Driving Amneal's 2026 Growth Outlook?
12:56pm, Tuesday, 09'th Jun 2026
AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
10:45am, Monday, 08'th Jun 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
12:30pm, Friday, 05'th Jun 2026
AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a potential boost to its injectables portfolio.
BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced new positive interim results from its ongoing Phas
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
02:08pm, Thursday, 04'th Jun 2026
Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approved its romidepsin injection solution, 27.5 mg/5.5 mL, in single-dose, ready-to-use vials. The produc
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
10:00am, Thursday, 04'th Jun 2026
Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approved its romidepsin injection solution, 27.5 mg/5.5 mL, in...
